What is CytomX Therapeutics's other commercial liabilities?

CytomX Therapeutics (CTMX) reported other commercial liabilities of $11.92M in Q1 2026.

How has CytomX Therapeutics's other commercial liabilities changed year-over-year?

CytomX Therapeutics's other commercial liabilities increased by 4.5% year-over-year, from $11.41M to $11.92M.

What is the long-term trend for CytomX Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), CytomX Therapeutics's other commercial liabilities has grown at a -9.2% compound annual growth rate (CAGR), from $23.06M to $14.2M.

CytomX Therapeutics CTMX Other Commercial Liabilities

Other Commercial Liabilities at other companies

AmgenAMGN

——

Janux TherapeuticsJANX

——

Vor BiopharmaVOR

——

Roivant SciencesROIV

——

Cullinan Therapeutics, Inc.CGEM

——

CRISPR TherapeuticsCRSP

——

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's other commercial liabilities?: CytomX Therapeutics (CTMX) reported other commercial liabilities of $11.92M in Q1 2026.
How has CytomX Therapeutics's other commercial liabilities changed year-over-year?: CytomX Therapeutics's other commercial liabilities increased by 4.5% year-over-year, from $11.41M to $11.92M.
What is the long-term trend for CytomX Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), CytomX Therapeutics's other commercial liabilities has grown at a -9.2% compound annual growth rate (CAGR), from $23.06M to $14.2M.